Inventor · disambiguated record
Mien-Chie Hung
Also filed as: HUNG MIEN-CHIE
34 granted patents·23 pending applications·365 citations·filing 1991–2025
97Inventor score
Top patents by PatentIndex Score
57 records- 0185US7816131B2Cancer specific promotersUNIV TEXAS·Filed 2005·Granted Oct 19, 2010·10 cites·9 claims
- 0284US10836827B2Antibodies specific to glycosylated PD-L1 and methods of use thereofSTCUBE INC·Filed 2016·Granted Nov 17, 2020·3 cites·24 claims
- 0383US10858432B2Antibodies specific to glycosylated PD-1 and methods of use thereofSTCUBE INC·Filed 2016·Granted Dec 8, 2020·3 cites·23 claims
- 0482US6683059B1Mini-E1A gene and gene productsUNIV TEXAS·Filed 2000·Granted Jan 27, 2004·14 cites·28 claims
- 0582US5651964AMethods for the suppression of neu mediated tumors by the adenoviral EIA geneUNIV TEXAS·Filed 1991·Granted Jul 29, 1997·46 cites·8 claims
- 0681US5653974APreparation and characterization of liposomal formulations of tumor necrosis factorUNIV TEXAS·Filed 1994·Granted Aug 5, 1997·63 cites·41 claims
- 0778US7316907B214-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer typesUNIV TEXAS·Filed 2004·Granted Jan 8, 2008·17 cites·18 claims
- 0878US5641484AMethods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigenUNIV TEXAS·Filed 1993·Granted Jun 24, 1997·59 cites·43 claims
- 0976US7906628B2Targeting proteins to deliver therapeutic or diagnostic reagentsUNIV TEXAS·Filed 2007·Granted Mar 15, 2011·3 cites·4 claims
- 1072US7005424B2Nucleic acid encoding an E1A gene product sensitizes HER-2/neu overexpressing cancer cells to chemotherapyUNIV TEXAS·Filed 2001·Granted Feb 28, 2006·2 cites·108 claims
- 1172US5643567AMethods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigenUNIV TEXAS·Filed 1994·Granted Jul 1, 1997·41 cites·22 claims
- 1271US11660352B2Dual function antibodies specific to glycosylated PD-L1 and methods of use thereofSTCUBE INC·Filed 2017·Granted May 30, 2023·1 cites·28 claims
- 1370US7893033B2Targeting proteins to deliver therapeutic or diagnostic reagentsUNIV TEXAS·Filed 2003·Granted Feb 22, 2011·3 cites·8 claims
- 1470US6395712B1Sensitization of HER-2/neu overexpressing cancer cells to chemotherapyUNIV TEXAS·Filed 1997·Granted May 28, 2002·22 cites·42 claims
- 1568US6197754B1Suppression of tumor growth by a mini-E1A geneUNIV TEXAS·Filed 1997·Granted Mar 6, 2001·20 cites·24 claims
- 1668US2024252542A1Exosome, preparation method thereof, use thereof and pharmaceutical compositionUNIV CHINA MEDICAL·Filed 2024·Application pending·0 cites
- 1767US11981736B2Antibodies specific to glycosylated PD-1 and methods of use thereofSTCUBE INC·Filed 2020·Granted May 14, 2024·0 cites·19 claims
- 1866US6331284B1P202 is a tumor suppressorUNIV TEXAS·Filed 2000·Granted Dec 18, 2001·5 cites·66 claims
- 1966US5922688APEA3 is a tumor suppressorUNIV TEXAS·Filed 1997·Granted Jul 13, 1999·30 cites·42 claims
- 2063US11452775B2Detection of arginine methylation of EGFR for prediction of resistance to therapyUNIV TEXAS·Filed 2019·Granted Sep 27, 2022·0 cites·15 claims
- 2162US7723104B2Cancer specific promotersUNIV TEXAS·Filed 2007·Granted May 25, 2010·0 cites·11 claims
- 2262US5814315AMethods for the suppression of neu mediated phenotype in tumorsUNIV TEXAS·Filed 1995·Granted Sep 29, 1998·13 cites·32 claims
- 2361US2005118154A1Antitumor effect of mutant BikFiled 2004·Application pending·0 cites
- 2460US10537635B2Detection of arginine methylation of EGFR for prediction of resistance to therapyUNIV TEXAS·Filed 2014·Granted Jan 21, 2020·0 cites·8 claims
- 2557US2024233572A1Virtual reality system of acupunctureUNIV CHINA MEDICAL·Filed 2024·Application pending·0 cites
- 2656US11933786B2Antibodies specific to glycosylated PD-L1 and methods of use thereofSTCUBE INC·Filed 2020·Granted Mar 19, 2024·0 cites·19 claims
- 2755US6582725B2Human PEA3 is a tumor suppressor for cancer cellsUNIV TEXAS·Filed 2001·Granted Jun 24, 2003·0 cites·14 claims
- 2855US2009075885A1Antitumor effect of mutant bikHUNG MIEN-CHIE·Filed 2008·Application pending·0 cites
- 2954US7709205B214-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer typeUNIV TEXAS·Filed 2007·Granted May 4, 2010·0 cites·9 claims
- 3053US8304526B2Antitumor effect of mutant BikHUNG MIEN-CHIE·Filed 2010·Granted Nov 6, 2012·0 cites·4 claims
- 3152US2024374529A1Pharmaceutical composition comprising polysaccharideHUNG MIEN CHIE·Filed 2022·Application pending·0 cites
- 3252US2021386695A1Use Of Disulfiram For Treating Infection Of SARS-COV-2UNIV CHINA MEDICAL·Filed 2021·Application pending·0 cites
- 3352US2022305015A1Combinatorial therapy targeting parp1 and rtkUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3451US2024261279A1Method for treating lung cancerHUNG MIEN CHIE·Filed 2022·Application pending·0 cites
- 3551US2005220781A1IFIX, a novel HIN-200 protein, for cancer therapyYAN DUEN-HWA·Filed 2004·Application pending·0 cites
- 3651US2021330661A1Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition ThereofUNIV CHINA MEDICAL·Filed 2021·Application pending·0 cites
- 3748US2025235481A1Genetically engineered mesenchymal stem cells and uses thereofUNIV CHINA MEDICAL·Filed 2025·Application pending·0 cites
- 3846US2021156866A1Detection of immune checkpoint molecules by deglycosylationUNIV TEXAS·Filed 2019·Application pending·0 cites
- 3946US2002169126A1Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic geneFiled 2002·Application pending·0 cites
- 4046US2024000742A1Method for treating lung cancerHUNG MIEN CHIE·Filed 2021·Application pending·0 cites
- 4145US6248351B1Human PEA3 is a tumor suppressor for cancer cellsUNIV TEXAS·Filed 1998·Granted Jun 19, 2001·8 cites·30 claims
- 4244US2003139344A1Antitumor activity of BokFiled 2002·Application pending·0 cites
- 4344US2022389106A1Anti-epha10 antibodies and methods of use thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4444US2019369106A1Flow proteometric methods for digital quantification and binding analysisUNIV TEXAS·Filed 2019·Application pending·0 cites
- 4544US2003228285A1Bipartite T-cell factor (Tcf)-responsive promoterFiled 2003·Application pending·0 cites
- 4643US12059474B2Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteinsSTCUBE & CO INC·Filed 2017·Granted Aug 13, 2024·0 cites·22 claims
- 4743US2009192101A1Cancer-specific promotersHUNG MIEN-CHIE·Filed 2007·Application pending·0 cites
- 4843US2003053995A1Methods and compositions for inhibiting EGF receptor activityFiled 2002·Application pending·0 cites
- 4942US11746152B2Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1STCUBE INC·Filed 2017·Granted Sep 5, 2023·0 cites·13 claims
- 5042US10451610B2Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1UNIV TEXAS·Filed 2015·Granted Oct 22, 2019·0 cites·18 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mien-Chie Hung files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →